



NEUROBIOLOGICAL CIRCUITS OF ADDICTION: SIGNIFICANCE FOR PSYCHIATRIC PRACTICE

**A Research Track from the
National Institute on Drug Abuse**

American Psychiatric Association

163rd Annual Meeting
New Orleans, LA
May 22-26, 2010



NIDA **NATIONAL INSTITUTE
ON DRUG ABUSE**

A collaboration of the
National Institute on Drug Abuse,
National Institutes of Health,
and the
American Psychiatric Association



May 2010

Dear Colleague:

On behalf of the National Institute on Drug Abuse (NIDA) and the American Psychiatric Association (APA), it is our privilege to welcome you to a special research-based program track—*Neurobiological Circuits of Addiction: Significance for Psychiatric Practice* during the 163rd APA Annual Meeting.

There is little doubt we are at a crossroads when it comes to opportunities to improve or optimize our approach to drug abuse and addiction, both scientifically and politically. From the scientific point of view, NIDA is beginning to reap the benefits from several decades of stunning advances in neuroscience. The combined progress provides the most detailed picture yet of the underlying risks, mechanistic triggers and functional correlates of the disease of addiction at the molecular, neurochemical, circuit, brain system, and environmental levels. The opportunities that these scientific advances are opening up for us to develop more effective prevention and treatment strategies are unprecedented. Equally exciting is the shift in focus that the new administration has imparted to its national drug policy, and its professed commitment to energizing prevention and treatment efforts. This new climate is poised to create far more fertile ground for the rapid and effective implementation of scientific discovery.

NIDA's special track will highlight a wide range of topics along this spectrum: from innovative technological advances such as the use of optogenetics and epigenetic research to elucidate the basic mechanisms underlying addictive behaviors to how the new knowledge is being translated into better prevention and treatments for drug use disorders. Special emphasis is given to sessions that touch upon the circuits in the brain that are involved with addiction but that are also disrupted in other mental illnesses. This new understanding of how mental illnesses disrupt brain function at the circuit level is giving new insights of why co-morbidity between drug use disorders and other psychiatric diseases is so frequent. Symposia and lectures will highlight areas critical to psychiatric practice including the unique issues facing military personnel and their families, the important clinical overlap of smoking with psychiatric disorders, an update on medications development for addiction, the commonalities between obesity and addiction, the potential therapeutic effects and abuse of cognitive enhancers, as well as novel approaches to stop the spread of HIV.

Scientific advances give hope to clinicians and their patients for better prevention and treatment of addiction and related mental illnesses. We are sure that the many activities planned for the NIDA track will reveal just how exciting the parallel and synergistic developments between science and practice are for our field.

Sincerely,

A handwritten signature in black ink, appearing to read "Nora D. Volkow".

Nora D. Volkow, M.D.
Director
National Institute on Drug Abuse

A handwritten signature in black ink, appearing to read "Alan F. Schatzberg".

Alan F. Schatzberg, M.D.
President
American Psychiatric Association



Contents

Planning Committee	4
Conference Information.	6
Agenda	7
Saturday, May 22, 2010	7
Sunday, May 23, 2010	9
Monday, May 24, 2010.	12
Tuesday, May 25, 2010	17
Wednesday, May 26, 2010	21
Notes	26



Planning Committee

National Institute on Drug Abuse

NIDA Staff

Nora D. Volkow, M.D.
Director
National Institute on Drug Abuse

Timothy P. Condon, Ph.D.
Deputy Director
National Institute on Drug Abuse

Lucinda L. Miner, Ph.D.
Deputy Director
Office of Science Policy and Communications

Susan R. B. Weiss, Ph.D.
Chief
Science Policy Branch
Office of Science Policy and Communications

Will M. Aklin, Ph.D.
Program Official
Behavioral and Integrative Treatment Branch
Division of Clinical Neuroscience and
Behavioral Research

Ruben D. Baler, Ph.D.
Health Scientist Administrator
Science Policy Branch
Office of Science Policy and Communications

James Bjork, Ph.D.
Program Official
Clinical Neuroscience Branch
Behavioral and Brain Development Branch
Division of Clinical Neuroscience and
Behavioral Research

Cheryl Anne Boyce, Ph.D.
Chief
Behavioral and Brain Development Branch
Associate Director for Child and Adolescent Research
Division of Clinical Neuroscience and
Behavioral Research

Wilson M. Compton, M.D., M.P.E.
Director
Division of Epidemiology, Services and
Prevention Research

Richard A. Denisco, M.D., M.P.H.
Medical Officer
Services Research Branch
Division of Epidemiology, Services and
Prevention Research

Joseph Frascella, Ph.D.
Director
Division of Clinical Neuroscience and
Behavioral Research

David A. Gorelick, M.D., Ph.D.
Intramural Research Program

Steven J. Grant, Ph.D.
Chief
Clinical Neuroscience Branch
Division of Clinical Neuroscience and
Behavioral Research

Mary A. Kautz, Ph.D.
Program Official
Clinical Neuroscience Branch
Division of Clinical Neuroscience and
Behavioral Research

Minda Lynch, Ph.D.
Chief
Behavioral and Cognitive Science Research Branch
Division of Basic Neuroscience and Behavioral Research

David J. McCann, Ph.D.
Acting Associate Director
Division of Pharmacotherapies and Medical
Consequences of Drug Abuse

Ivan D. Montoya, M.D., M.P.H.
Acting Deputy Director
Division of Pharmacotherapies and Medical
Consequences of Drug Abuse

Eve Reider, Ph.D.
Acting Chief
Prevention Research Branch
Division of Epidemiology, Services and
Prevention Research

Jeffrey D. Schulden, M.D.
Medical Officer
Epidemiology Research Branch
Division of Epidemiology, Services and
Prevention Research

Jane E. Smither
Constituent Liaison
Science Policy Branch
Office of Science Policy and Communications

Roger G. Sorensen, Ph.D., M.P.A.
Health Scientist Administrator
Functional Neuroscience Research Branch
Division of Basic Neuroscience and Behavioral Research

Cecelia M. Spitznas, Ph.D.
Program Official
Behavioral and Integrative Treatment Branch
Division of Clinical Neuroscience and
Behavioral Research

Susan Volman, Ph.D.
Health Scientist Administrator
Behavioral and Cognitive Science Research Branch
Division of Basic Neuroscience and Behavioral Research

Cora Lee Wetherington, Ph.D.
Women and Sex/Gender Differences Research
Coordinator and Health Scientist Administrator
Behavioral and Cognitive Science Research Branch
Division of Basic Neuroscience and Behavioral Research

American Psychiatric Association

Alan F. Schatzberg, M.D.
President
American Psychiatric Association (APA)

John A. Renner, Jr., M.D.
Associate Professor of Psychiatry
Boston University School of Medicine
Associate Chief of Psychiatry
VA Boston Healthcare System

Shelly F. Greenfield, M.D., M.P.H.
Associate Professor in Psychiatry
Harvard Medical School
Director
Clinical and Health Services Research
Division on Alcohol and Drug Abuse
McLean Hospital

Herbert D. Kleber, M.D.
Professor of Psychiatry and Director
Division on Substance Abuse
Columbia University

APA Staff

Deborah J. Hales, M.D.
Director
APA Division of Education

Darrel A. Regier, M.D., M.P.H.
Executive Director
American Psychiatric Institute for Research and
Education
Director
APA Office of Research

Beatrice A. Eld
Associate Director
APA Department of Quality Improvement and
Psychiatric Services

Joy Raether
Associate Director
Conference and Online Continuing Medical Education
(CME)

Diane Runels
CME Course Administrator

Conference Information

This program book provides information about workshops, lectures, and symposia organized by the National Institute on Drug Abuse (NIDA). These activities are highlighted in blue.

NIDA has also included a number of other sessions from the American Psychiatric Association (APA) program based on scientific content that complements the theme. Sessions included in NIDA's Research Track, as well as other sessions related to substance use and addiction, are also listed in the APA Annual Meeting Program Guide. Abstracts of all sessions are included on a CD provided to all attendees.

Invited Lectures

Nora D. Volkow, M.D., Director, NIDA, Frontiers of Science Lecture on *Addiction: Conflict Between Brain Circuits* on Tuesday, May 25, 2010, 9:00 a.m., Morial Convention Center, Hall A (Session #L12).

Karl Deisseroth, M.D., Ph.D., Frontiers of Science Lecture on *Optogenetics: Development and Application* on Monday, May 24, 2010, 11:00 a.m., Morial Convention Center, La Louisiane Room A/B (Session #L6).

A. Thomas McLellan, Ph.D., Lecture on *New Directions in Drug Policy: President Obama's National Demand Reduction Priorities* on Tuesday, May 25, 2010, 1:30 p.m., Morial Convention Center, Room R02-05 (Session #L16).

Julio Montaner, M.D., Frontiers of Science Lecture on *Seek and Treat for Optimal Prevention of HIV/AIDS: STOP HIV/AIDS* on Wednesday, May 26, 2010, 11:00 a.m., Morial Convention Center, Room R02-05 (Session #L21).

Continuing Medical Education (CME)

The APA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 50 AMA PRA Category 1 Credits™.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

Exhibit

A wide variety of materials are available at the NIDA exhibit, Booth 1033, Halls B-D, Morial Convention Center. Please allow time to visit the NIDA exhibit to learn more about drug abuse.

Website

Information about NIDA research, programs, and events is accessible through NIDA's website at www.drugabuse.gov.

Agenda

Saturday, May 22, 2010

9:00 a.m. – 11:00 a.m.

Symposium (Session #S3)

Smoking and Psychiatric Disorders: Clues About Causal Pathways and Innovative Treatment Approaches

Morial Convention Center, Room 223

Co-Chairs:

Jeffrey D. Schulden, M.D.
National Institute on Drug Abuse

Wilson M. Compton, M.D., M.P.E.
National Institute on Drug Abuse

Speakers:

Lisa Dierker, Ph.D.
Wesleyan University
Psychiatric Disorders as Signals of Sensitivity for Nicotine Dependence

Robert Freedman, M.D.
University of Colorado
Nicotine Receptors and Their Genes in Psychosis

Douglas M. Ziedonis, M.D.
University of Massachusetts Medical School
Integrating Tobacco Dependence Treatment Into Mental Health and Addiction Treatment

2:00 p.m. – 5:00 p.m.

Symposium (Session #S29)

Executive Function as a Brain System for Self-Control: The Neurocircuitry of Psychiatric Disorders and Addiction

Morial Convention Center, Room 355

Co-Chairs:

Mary A. Kautz, Ph.D.
National Institute on Drug Abuse

Minda Lynch, Ph.D.
National Institute on Drug Abuse

(Session continued on next page)

Shaded entries indicate NIDA-organized sessions.

(Session continued from previous page)

- Speakers: Earl K. Miller, Ph.D.
Massachusetts Institute of Technology
Prefrontal Circuits for Rules, Concepts, and Cognitive Control
- Todd Hare, Ph.D.
California Institute of Technology
Basic Neurobiology of Self-Control in Decision Making
- Karen Faith Berman, M.D.
National Institute of Mental Health
Key Circuits and Regions Implicated in Executive Dysfunction and Disruptions of Cognitive Control in Schizophrenia: Genetic Influences and Dopamine Regulation
- Kevin N. Ochsner, Ph.D.
Columbia University
Core Cognitive Systems for Controlling Craving and Negative Emotion in Substance Abuse and Psychiatric Disorders
- Discussant: Trevor Robbins, Ph.D.
University of Cambridge

2:00 p.m. – 5:00 p.m.

Symposium (Session #S30)
Addiction Research, Prevention, and Treatment in the United States and France: Vive la Difference!
Morial Convention Center, Room 356/357

Chair: John A. Talbott, M.D.
University of Maryland School of Medicine

Speakers: Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse
Progress in Addiction Research

Marc-Antoine Crocq, M.D.
Centre Hospitalier
Patterns of Addiction in High School and University Students

(Session continued on next page)

Saturday, May 22/Sunday, May 23

(Session continued from previous page)

Speakers: Joshua Sharfstein, M.D.
U.S. Food and Drug Administration (FDA)
The FDA and Tobacco Regulation

Renaud de Beaurepaire, M.D.
Paul Guiraud Hospital
Do Psychiatric Patients Smoke to Self-Medicate, or Is It for Other Reasons?

David Oslin, M.D.
University of Pennsylvania Medical Center
The State of Treatment of Addictive Disorders in the United States

Amine Benyamina, M.D.
Paul Brousse University Hospital
Organization and Health Care Networks for Cannabis Treatment in France

Sunday, May 23, 2010

9:00 a.m. – 12:00 p.m.

Symposium (Session #S35)
**Sex/Gender Differences and Women-Specific Issues in Drug Abuse:
Predicting and Improving Treatment Outcomes**
Morial Convention Center, Room 353

Co-Chairs: Cora Lee Wetherington, Ph.D.
National Institute on Drug Abuse

Shelly Greenfield, M.D., M.P.H.
Harvard Medical School

Speakers: Kathleen Brady, M.D., Ph.D.
Medical University of South Carolina
Gender Differences in Psychiatric Comorbidity With Substance Use Disorder: Implications for “Telescoping” and Treatment

(Session continued on next page)

Shaded entries indicate NIDA-organized sessions.

(Session continued from previous page)

- Speakers: Rajita Sinha, Ph.D.
Yale University School of Medicine
Significant Role of Sex-Based Biology in Predicting Relapse and Clinical Outcomes in Drug Abuse
- Shelly Greenfield, M.D., M.P.H.
Harvard Medical School
Women-Focused Treatment for Substance Use Disorders: Results From the Women's Recovery Group Study
- Denise Hien, Ph.D.
Columbia University
Substance-Abusing Women With PTSD: How Best to Treat?
- Theresa Winhusen, Ph.D.
University of Cincinnati College of Medicine
The Use of Motivational Enhancement Therapy and Vouchers to Improve Treatment Utilization and Outcome in Pregnant Substance Users

1:30 p.m. – 3:00 p.m.

Workshop (Session #W56)
Maintenance Treatment for Opiate Dependence: Terminable or Intermittent?
Morial Convention Center, Room 346

- Co-Chairs: Ivan D. Montoya, M.D., M.P.H.
National Institute on Drug Abuse
- Herbert D. Kleber, M.D.
Columbia University
- Speakers: Steven Batki, M.D.
University of California, San Francisco
- Robert Schwartz, M.D.
Friends Research Institute
- Kenzie Preston, Ph.D.
National Institute on Drug Abuse

2:00 p.m. – 5:00 p.m.

Symposium (Session #S36)

Treating Chronic Pain and Co-occurring Addiction in Substance Abuse Patients

Morial Convention Center, Room 347

Co-Chairs: Richard A. Denisco, M.D., M.P.H.
National Institute on Drug Abuse

Will M. Aklin, Ph.D.
National Institute on Drug Abuse

Speakers: Ian R. Carroll, M.D., M.P.H.
Stanford University
Why Do Some Patients Have Persistent Pain and Persistent Opioid Use Following Surgery: An Inception Cohort Study?

Steve Passik, Ph.D.
Memorial Sloan-Kettering Cancer Center
Clinical Aspects of Risk Management in Opioid Therapy

Declan T. Barry, Ph.D.
Yale University
Behavioral Treatment for Co-occurring Chronic Pain and Opioid Addiction

Roger D. Weiss, M.D.
Harvard University
Results of the Prescription Opioid Addiction Treatment Study: A Multisite Trial of the NIDA Clinical Trials Network

Sean Mackey, M.D., Ph.D.
Stanford University School of Medicine
Overview of the Treatment of Acute and Chronic Pain in the Patient With a History of Addiction

Monday, May 24, 2010

9:00 a.m. – 12:00 p.m.

Symposium (Session #S42)

Update on Medications Development: Promising New Treatments for Drug Addiction

Morial Convention Center, Room 356/357

Co-Chairs:

Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse

David J. McCann, Ph.D.
National Institute on Drug Abuse

Speakers:

Charles O'Brien, M.D., Ph.D.
University of Pennsylvania School of Medicine
Modafinil as a Novel Medication in the Treatment of Cocaine Addiction

Kathleen Brady, M.D., Ph.D.
Medical University of South Carolina
D-Cycloserine in the Treatment of Cocaine and Nicotine Dependence

David J. McCann, Ph.D.
National Institute on Drug Abuse
Bupropion for the Treatment of Methamphetamine Addiction

Frances R. Levin, M.D.
Columbia University
Dronabinol for Cannabis Addiction Treatment

Raafat Fahim, Ph.D.
Nabi Biopharmaceuticals
NicVAX: An Innovative Vaccine Treatment for Nicotine Addiction

Discussant:

Herbert D. Kleber, M.D.
Columbia University

11:00 a.m. – 12:30 p.m.

Frontiers of Science Lecture (Session #L6)

Optogenetics: Development and Application

Morial Convention Center, La Louisiane Room A/B

Speaker: Karl Deisseroth, M.D., Ph.D.
Stanford University

2:00 p.m. – 5:00 p.m.

Presidential Symposium (Session #PS03)

Can Basic and Translational Neuroscience Improve Treatment in Psychiatry?

Morial Convention Center, Room 220-222

Co-Chairs: Alan F. Schatzberg, M.D.
President, American Psychiatric Association
Stanford University

Karl Deisseroth, M.D., Ph.D.
Stanford University

Speakers: Kerry Ressler, M.D., Ph.D.
Emory University
Translational Studies in Genetics: Genetic Tools in Animal Models to Understand Heritable Risk Factors in Depression and Posttraumatic Stress Disorder

Amit Etkin, M.D., Ph.D.
Stanford University
Emotion Regulation: Toward a Neurobiological Understanding of Psychotherapy

Karl Deisseroth, M.D., Ph.D.
Stanford University
Optogenetics: Development and Application

Vikaas Sohal, M.D., Ph.D.
Stanford University
Using Optogenetic Tools and Information Theory to Elucidate Prefrontal Microcircuit Dysfunction in Schizophrenia

2:00 p.m. – 5:00 p.m.

Symposium (Session #S52)

Innovations in Integrated Treatment of Substance Use and Psychiatric Disorders

Morial Convention Center, Room 338/339

Co-Chairs:

Ivan D. Montoya, M.D., M.P.H.
National Institute on Drug Abuse

Wilson M. Compton, M.D., M.P.E.
National Institute on Drug Abuse

Speakers:

Paul Rohde, Ph.D.
Oregon Research Institute
Integrated Treatment of Depression and Substance Use Disorders in Adolescents

Kathleen Brady, M.D., Ph.D.
Medical University of South Carolina
Posttraumatic Stress Disorder and Drug Abuse: Etiology and Treatment Linkages

Roger D. Weiss, M.D.
Harvard University
Integrated Group Therapy for Patients With Co-occurring Bipolar Disorder and Substance Use Disorder

Edward V. Nunes, M.D.
Columbia University
Advances in Pharmacotherapy for Comorbid Depression and Addictions

Alan I. Green, M.D.
Dartmouth University
Treatment of Cannabis Use Disorder in Patients With Schizophrenia

Discussant:

Stanley Sacks, Ph.D.
Center for the Integration of Research and Practice

Monday, May 24

2:00 p.m. – 5:00 p.m.

Symposium (Session #S54)

Substance Related Disorders in DSM-5: Progress Report

Morial Convention Center, Room 342

Co-Chairs: Charles O'Brien, M.D., Ph.D.
University of Pennsylvania School of Medicine

Deborah S. Hasin, Ph.D.
Columbia University

Speakers: Marc Schuckit, M.D.
University of California, San Diego
The Search for Specific Criteria: A Report From the Criterion Subcommittee

Deborah S. Hasin, Ph.D.
Columbia University
Abuse and Dependence: Combining the Disorders Into a Single Category

Nancy M. Petry, Ph.D.
University of Connecticut Health Center
Non-Substance Related Addictions: Their Place in DSM-V

Wilson M. Compton, M.D., M.P.H.
National Institute on Drug Abuse
Terminology of Substance Use Disorders for DSM-V

Thomas J. Crowley, M.D.
University of Colorado, Denver
Severity of Substance Use Disorders

2:00 p.m. – 5:00 p.m.

Symposium (Session #S59)

Neurobiology of Obesity: Why We Can Get Too Motivated to Eat

Morial Convention Center, Room 356/357

Co-Chairs: Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse

Joseph Frascella, Ph.D.
National Institute on Drug Abuse

(Session continued on next page)

Shaded entries indicate NIDA-organized sessions.

(Session continued from previous page)

- Speakers: David A. Kessler, M.D.
University of California, San Francisco
Overeating and Obesity: Any End in Sight to Our "Addiction" to Food?
- Hans-Rudolf Berthoud, Ph.D.
Pennington Biomedical Research Center, Louisiana State University
Central Control of Food Intake: Appetite Control and the Reward-Driven Brain
- Serge Ahmed, Ph.D.
University of Bordeaux
Sweetness as a Super Reward: Comparison With Cocaine and Heroin
- Cary R. Savage, Ph.D.
University of Kansas Medical Center
Functional Neuroimaging in Obese and Healthy Weight Groups: Food Motivation and Monetary Reward
- Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse
Neurocircuitry of Addiction and Obesity
- Discussant: Nora D. Volkow, M.D.

3:30 p.m. – 5:00 p.m.

Scientific and Clinical Reports (Session #SCR13)

Addictive Behavior

Morial Convention Center, Room 348/349

- Speakers: Deepak Prabhakar, M.D., M.P.H.
Wayne State University-Detroit Medical Center
Disparities in Substance Abuse Prevalence: Is It Time to Strategize and Refocus?

(Session continued on next page)

Monday, May 24/Tuesday, May 25

(Session continued from previous page)

Speakers: Pinhas Dannon, M.D.
Beer Yaacov Mental Health Hospital
Pathological Gambling: An Impulse Control Disorder?
Measurement of Impulsivity Through Neurocognitive Tests

David A. Gorelick, M.D., Ph.D.
National Institute on Drug Abuse
Quitting Cannabis Use Without Formal Treatment in Adults

Tuesday, May 25, 2010

9:00 a.m. – 10:30 a.m. Frontiers of Science Lecture (Session #L12)
Addiction: Conflict Between Brain Circuits
Morial Convention Center, Hall A

Speaker: Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse

9:00 a.m. – 11:00 a.m. Symposium (Session #S63)
Adolescent Potential: Exploring the Developing Brain and Understanding Pathways of Addiction
Morial Convention Center, Room 238/239

Co-Chairs: Cheryl Anne Boyce, Ph.D.
National Institute on Drug Abuse

Joseph Frascella, Ph.D.
National Institute on Drug Abuse

Speakers: Linda Spear, Ph.D.
State University of New York at Binghamton
The Developing Brain, Adolescence, and Alcohol/Drug Use: An Evolutionary Approach

(Session continued on next page)

Shaded entries indicate NIDA-organized sessions.

(Session continued from previous page)

- Speakers: Jay N. Giedd, M.D.
National Institute of Mental Health
The Teen Brain: Insights From Neuroimaging
- Beatriz Luna, Ph.D.
University of Pittsburgh Medical Center
Vulnerabilities in Adolescent Decision Making: Neuroimaging Evidence of Immaturities in Cognitive Control, Reward Processing, and Brain Connectivity
- Susan F. Tapert, Ph.D.
University of California, San Diego
Brain Functioning in Adolescent Substance Using Boys and Girls

9:00 a.m. – 12:00 p.m.

Symposium (Session #S68)
Reward Neurocircuitry in Substance Dependence and Other Psychiatric Disorders: What Does Brain Research Tell Us?
Morial Convention Center, Room 352

Co-Chairs: Susan Volman, Ph.D.
National Institute on Drug Abuse

James Bjork, Ph.D.
National Institute on Drug Abuse

Speakers: Susan R. Sesack, Ph.D.
University of Pittsburgh
Reward Neurocircuitry in Preclinical Models: Foundations and Alterations With Drug Use

Mauricio Delgado, Ph.D.
Rutgers University
Functional Neuroimaging of Neural Circuits Regulating Aversive Emotional Reactions and Expectations of Reward

(Session continued on next page)

(Session continued from previous page)

Speakers: Wayne C. Drevets, M.D.
Oklahoma University College of Medicine
Neuroimaging Studies of Reward Processing in Major Depressive Disorder

Elliot Hong, M.D.
Maryland Psychiatric Research Center
Association of Nicotine Addiction and Nicotine's Actions With Separate Cingulate Cortex Functional Circuits

James M. Swanson, Ph.D.
University of California Irvine School of Medicine
PET Evaluation of Neurocircuitry Related to Etiology and Treatment of ADHD

11:00 a.m. – 12:30 p.m.

Small Interactive Session (Session #SI15)
Addiction and the Brain
(Limited to Resident Members of APA on a First-Come/First-Served Basis)
Morial Convention Center, Room 237

Speaker: Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse

1:30 p.m. – 3:00 p.m.

Lecture (Session #L16)
New Directions in Drug Policy: President Obama's National Demand Reduction Priorities
Morial Convention Center, Room R02-05

Speaker: A. Thomas McLellan, Ph.D.
Deputy Director, White House Office of National Drug Control Policy

Tuesday, May 25

2:00 p.m. – 5:00 p.m.

Advances in Series (Session #A07)

Advances in Substance Abuse Treatment

Morial Convention Center, Room 353-355

Co-Chairs: Marc Galanter, M.D.
New York University School of Medicine

Herbert D. Kleber, M.D.
Columbia University

Speakers: John A. Renner, Jr., M.D.
Boston University School of Medicine
The Use of Buprenorphine in the Treatment of Opioid Dependence

Hendree E. Jones, M.D.
Johns Hopkins Bayview Medical Center
The Treatment of Perinatal Addiction

Mark S. Gold, M.D.
McKnight Brain Institute, University of Florida
Treatment of Marijuana Abuse and Dependence

Richard K. Ries, M.D.
Harborview Medical Center
Treatment of the Dually Diagnosed

Harrison G. Pope, Jr., M.D.
McLean Hospital
Treatment of Anabolic-Androgenic Steroid Abuse

2:00 p.m. – 5:00 p.m.

Symposium (Session #S79)

The Challenge of Cognitive Enhancers in Medicine

Morial Convention Center, Room 338/339

Co-Chairs: Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse

Ruben D. Baler, Ph.D.
National Institute on Drug Abuse

(Session continued on next page)

(Session continued from previous page)

- Speakers:
- Herbert Y. Meltzer, M.D.
Vanderbilt University
5-HT Receptors as Targets for Cognitive Enhancement in Schizophrenia
- Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse
ADHD Treatment, Comorbidity With SUDs, and COGS-Related Diversion
- Charles Dackis, M.D.
University of Pennsylvania
Modafinil's Abuse Potential and Possible Role in Cocaine Dependence
- James M. Ellison, M.D., M.P.H.
Harvard Medical School
Nonimpaired Elders, Cognitive Enhancers, and the Boundaries of Usual and Customary Practice
- Barbara Sahakian, M.D.
University of Cambridge
Pharmacological Cognitive Enhancement in Neuropsychiatric Disorders and in Healthy People

Wednesday, May 26, 2010

- 9:00 a.m. – 12:00 p.m.
- Symposium (Session #S86)
How Dysfunction of Learning and Memory Circuits Contribute to Substance Abuse and Other Psychiatric Disorders
Morial Convention Center, Room 224
- Co-Chairs:
- Roger G. Sorensen, Ph.D., M.P.A.
National Institute on Drug Abuse
- Steven J. Grant, Ph.D.
National Institute on Drug Abuse

(Session continued on next page)

(Session continued from previous page)

- Speakers: Mark A. Gluck, Ph.D.
Rutgers University
Selective Impairments in Reward vs. Punishment Learning in Psychiatric Disorders
- A. David Redish, Ph.D.
University of Minnesota
Addiction as Dysfunction in Learning-and-Memory-Based Decision Systems: Multiple Potential Failure Points Leading to Multiple Addiction Endophenotypes
- Anna Rose Childress, Ph.D.
University of Pennsylvania School of Medicine
Impaired Modulation of Learned Motivational Responses to Cues: Common Core Dysfunctions in Addiction—and in PTSD
- Peter W. Kalivas, Ph.D.
Medical University of South Carolina
Neuroplasticity in Prefrontal Regulation of the Basal Ganglia Underlies Vulnerability to Relapse
- Kevin S. LaBar, Ph.D.
Duke University
Emotional Influences on Memory Circuits in Posttraumatic Stress Disorder and Healthy Adults

9:00 a.m. – 12:00 p.m.

Symposium (Session #S92)
Update on Cannabis Use Disorders
Morial Convention Center, Room 340/341

Chair: David A. Gorelick, M.D., Ph.D.
National Institute on Drug Abuse

Speakers: Deborah S. Hasin, Ph.D.
Columbia University
Marijuana Abuse and Dependence in the General Population: Risk Factors, Symptom Structure, and Axis I and Axis II Comorbidity Effects on Persistence

(Session continued on next page)

(Session continued from previous page)

- Speakers: Aviv M. Weinstein, B.S.C.
Hadassah Medical Organization
Neurobiology and Brain Imaging of Cannabis Dependence
- Alan Budney, Ph.D.
University of Arkansas
Advances in the Development of Behavioral Treatments for Cannabis Use Disorders
- Margaret Haney, Ph.D.
Columbia University
Advances in the Development of Pharmacological Treatments for Cannabis Use Disorders
- David A. Gorelick, M.D., Ph.D.
National Institute on Drug Abuse
Medical and Psychiatric Effects Associated With Cannabis Use

9:00 a.m. - 12:00 p.m.

Symposium (Session #S94)
Choosing the Right Treatment for Substance Abuse
Morial Convention Center, Rooms 346/347

- Chair: Herbert D. Kleber, M.D.
Columbia University
- Speakers: Adam Bisaga, M.D.
Columbia University
Choosing the Right Treatment for Cocaine Dependence
- Frances R. Levin, M.D.
Columbia University
Choosing Treatments for Cannabis Dependence: What are the Options?

(Session continued on next page)

(Session continued from previous page)

Speakers: Edward V. Nunes, M.D.
Columbia University
Principles of Combining Medications and Psychosocial Interventions in the Treatment of Substance Dependence

Maria A. Sullivan, M.D., Ph.D.
Columbia University
Pain and Addiction: Substance Use Disorders in the Context of Opioid Therapy

9:00 a.m. – 12:00 p.m.

Symposium (Session #S98)
Novel Tools for Preventing and Treating Substance Use and Comorbidities in the Military and Returning Veterans
Morial Convention Center, Room 356/357

Co-Chairs: Cecelia M. Spitznas, Ph.D.
National Institute on Drug Abuse

Eve Reider, Ph.D.
National Institute on Drug Abuse

Speakers: Tyler C. Smith, Ph.D., M.S.
Naval Health Research Center
Understanding Long-Term Tobacco and Alcohol Use and Comorbid Mental Health Symptoms in Military Service Members and Veterans: The Millennium Cohort Study

Magdalena R. Naylor, M.D., Ph.D.
University of Vermont College of Medicine
Automated Interactive Voice Response as a Therapeutic Tool for Chronic Pain Reduction and Opioid Medication Use Decrease

Barbara Rothbaum, Ph.D.
Emory School of Medicine
Virtual Reality and D-Cycloserine for Exposure-Based Therapy

(Session continued on next page)

(Session continued from previous page)

Speakers: Barbara Gerbert, Ph.D.
University of California, San Francisco
*The Video Doctor Approach: Potential Applications to
Psychiatric Practices Serving Patients Impacted by War*

Kathleen M. Carroll, Ph.D.
Yale University School of Medicine
*Computer-Based Training in Cognitive Behavioral Therapy:
New Findings and Applications for Military Personnel*

Discussant: Michael Kilpatrick, M.D.
U.S. Department of Defense

11:00 a.m. – 12:30 p.m. Frontiers of Science Lecture (Session #L21)
Seek and Treat for Optimal Prevention of HIV/AIDS: STOP HIV/AIDS
Morial Convention Center, Room R02-05

Speaker: Julio Montaner, M.D.
University of British Columbia

Notes

Notes

